Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES

Eur J Prev Cardiol. 2024 Aug 9;31(10):e75-e78. doi: 10.1093/eurjpc/zwae110.
No abstract available

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Anticholesteremic Agents / adverse effects
  • Anticholesteremic Agents / therapeutic use
  • Biomarkers / blood
  • Cardiovascular Diseases* / blood
  • Cardiovascular Diseases* / epidemiology
  • Dyslipidemias / blood
  • Dyslipidemias / diagnosis
  • Dyslipidemias / drug therapy
  • Dyslipidemias / epidemiology
  • Female
  • Humans
  • Lipoprotein(a)* / blood
  • Male
  • Middle Aged
  • PCSK9 Inhibitors
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Lipoprotein(a)
  • alirocumab
  • Biomarkers
  • PCSK9 Inhibitors
  • Anticholesteremic Agents
  • LPA protein, human